BioPharmSignal logoBioPharmSignal

Biotech News

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026

Beyond Air (XAIR)Beyond AirEarnings

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its quarter ended September 30, 2026 on Wednesday, November 11, 2026. The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. Eastern Time (ET) the same day.

Related news

XAIRBeyond Air2026-10-08 12:00 EST

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

AORTArtivion2026-10-22 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results

SENSSenseonics2026-10-21 12:00 EST

Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time

IRMDiRadimed2026-10-23 12:30 EST

IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

STIMNeuronetics2026-10-21 12:30 EST

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

IARTIntegra LifeSciences2026-10-06 12:30 EST

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

AORTArtivion2026-11-05 21:05 EST

Artivion Reports Third Quarter 2026 Financial Results

View all latest news

Beyond Air

Nitric Oxide Medical Technology Platform Beyond Air is a commercial-stage medical device and biopharmaceutical company developing nitric oxide-based products for respiratory disease, neurological conditions, and solid tumors. Its first product, LungFit PH, is FDA-approved and CE-marked for hypoxic respiratory failure in term and...

Recent company news

XAIRBeyond Air2026-10-29 12:00 EST

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026

XAIRBeyond Air2026-10-08 12:00 EST

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

XAIRBeyond Air2026-09-02 12:00 EST

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference

XAIRBeyond Air2026-08-31 12:00 EST

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

XAIRBeyond Air2026-08-25 11:00 EST

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

Stock data

Close
2.18 USD
Market cap
5.97M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States